Ischemic stroke (IS) is a devastating disease with high disability and mortality rates worldwide. Despite advances in medical treatment, managing IS remains a significant challenge. In China, traditional Chinese herbal medicines (TCHMs) are often sought as alternative pharmacotherapies for both prevention and rehabilitation because of their proven efficacy and relatively low incidence of adverse reactions. While TCHMs do have certain limitations, their value cannot be overlooked. Centuries of clinical experience in China have established TCHMs as promising approaches for improving clinical outcomes and accelerating drug discovery in the treatment of IS. In this review, we summarize the potential mechanisms and clinical evidence of TCHMs in the treatment of IS in China. These findings suggest that TCHMs can treat IS through various pharmacological mechanisms, mainly anti-inflammatory, antiapoptotic, antioxidative stress, and mitochondrial regulatory mechanisms. Additionally, TCHMs provide protection to the blood-brain barrier, inhibit excitotoxicity, promote angiogenesis, reduce ferroptosis, modulate the gut-brain axis, prevent thrombosis, improve blood rheology, and regulate neural stem cells. These effects contribute to improved therapeutic outcomes at various stages of IS and poststroke complications, especially when combined with Western medicine, while also offering a favorable safety profile. In conclusion, TCHMs represent a promising strategy for managing IS and advancing related drug development. We hope that this review will inspire further exploration into the mechanisms underlying the anti-IS effects of TCHMs, thereby enhancing the scientific understanding of traditional Chinese medicine.
Astragalus membranaceus (Fisch.) Bunge is a fundamental herb in traditional Chinese medicine. It has a long history of use in clinical practice for treating stroke and its associated sequelae. Notably, Formononetin (FN) has been identified as a primary bioactive isoflavone in this herb. However, its specific function in cerebral ischemia‒reperfusion injury remains unclear, especially regarding the area of immunometabolic regulation. Ischemic stroke remains a major cause of neurological disability worldwide. Although reperfusion is crucial for salvaging the ischemic penumbra, it also contributes to secondary injury driven by microglial activation. Emerging evidence suggests that targeting metabolic immune interactions may help mitigate postreperfusion neuroinflammation. This study aimed to investigate whether FN attenuates cerebral ischemia‒reperfusion injury by modulating microglial metabolism and polarization. A transient middle cerebral artery occlusion (tMCAO) model was established in mice. Formononetin (FN) was administered immediately after reperfusion. Neurological deficit scores were assessed daily for three days. Twenty-four hours after reperfusion, pathological injury was evaluated by hematoxylin and eosin (H&E) staining and a TUNEL assay. Microglial polarization markers were analyzed using immunofluorescence and Western blotting. Inflammatory cytokines were measured by real-time quantitative polymerase chain reaction (RT‒qPCR) and enzyme-linked immunosorbent assay (ELISA). RNA sequencing was performed on peri-infarct cortical tissue to identify affected pathways. Glycolytic protein levels in the same region were measured by western blotting. Molecular docking was employed to predict key bioactive compounds and their potential targets. These predictions were further validated by Western blot analysis. For in vitro studies, BV2 cells were subjected to oxygen‒glucose deprivation and reperfusion (OGD/R). Polarization markers were subsequently detected by flow cytometry and RT‒qPCR. Cellular ATP and lactate levels, glucose uptake, the extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) were measured. An AMPK inhibitor was used for intervention in both in vivo and in vitro experiments. Key indicators related to AMPK signaling, microglial polarization, and glycolysis were examined via immunofluorescence and Western blotting. FN treatment improved neurological function scores, reduced infarct volume, and attenuated pathological injury in tMCAO mice. Both in vivo and in vitro, FN treatment inhibited glycolysis and enhanced mitochondrial oxidative metabolism. It also decreased M1-like polarization while increasing M2-like polarization markers, leading to a reduction in proinflammatory cytokine production. RNA sequencing and molecular docking analysis revealed the AMPK/mTOR/HIF-1⍺ pathway, which was subsequently confirmed at the protein level. An AMPK inhibitor reversed the FN-induced changes in both metabolic and microglial phenotypes. FN suppresses glycolytic metabolism in microglia through AMPK signaling, thereby influencing microglial polarization and attenuating neuroinflammation.
Rationale: Unconsciousness is a nonfocal symptom of transient ischemic attack (TIA) that is frequently observed in patients with vertebrobasilar artery stenosis or occlusion. Conversely, loss of consciousness due to anterior circulation involvement (e.g., middle cerebral artery [MCA]) is a rare occurrence in TIA. Patient concerns: This report describes a rare case in a 59-year-old woman who experienced recurrent episodes of altered consciousness because of the occlusion or stenosis of her MCAs. Diagnoses: The diagnosis of the case was updated from TIA to acute cerebral infarction, finally. Following initial loss of consciousness, cranial magnetic resonance imaging (MRI) did not reveal any evidence of acute cerebral infarction. However, following the second and third episodes of unconsciousness, the MRI revealed multiple new acute cerebral infarcts affecting both the cerebral hemispheres. Further evaluation through digital subtraction angiography disclosed complete occlusion of the left MCA and severe stenosis of the right MCA. Interventions: Early in her illness, the patient was treated with vasodilators, aspirin and atorvastatin. Finally, 2 stents in her right and left MCAs were placed respectively, followed by treatment with aspirin, clopidogrel, and double-dosed atorvastatin calcium. Meanwhile, the patient focused on avoiding conditions which may lead to dehydration in her daily life routine. Outcomes: The episodes of unconsciousness of this patient were completely resolved. During the 1-year postoperative follow-up, the patient remained clinically stable without any symptoms of unconsciousness, limb numbness or weakness, or dizziness. Lessons: These findings suggested that hypoperfusion in the bilateral cerebral hemispheres played a pivotal role in precipitating the patient episodes of unconsciousness. This case underscores the possibility that occlusion or severe stenosis in both MCAs can contribute to recurrent episodes of unconsciousness due to hypoperfusion. Moreover, it emphasizes the association between these episodes of unconsciousness and an increased risk of subsequent ischemic stroke.